Press releases
-
November
26
ADVITECH ANNOUNCES THE MERGER OF ITS OPERATIONS WITH BOTANECO, THE CLOSING OF A $2.5M EQUITY FINANCING AND THE APPOINTMENT OF A NEW PRESIDENT AND CHIEF EXECUTIVE OFFICER
TSX VENTURE EXCHANGE: AVI For immediate release
This news release is intended for distribution in Canada only and is not intended for distribution to United States newswire services or dissemination in the United States.
QUEBEC CITY, QUEBEC - November 26, 2009 - Advitech Inc. ("Advitech" or the "Corporation") (TSX Venture Exchange: AVI) announced today that, further to the consolidation of its common shares on a 8-for-1 basis (the "Consolidation"), the TSX Venture Exchange Inc. (the "TSX-V") has approved the release from escrow of the previously announced acquisition of all the issued and outstanding shares of Botaneco Specialty Ingredients Inc. ("Botaneco") held by Avrio Ventures Limited Partnership ("Avrio") and SemBioSys Genetics Inc. ("SemBioSys") (the "Transaction"), an equity financing in the amount of $2,515,000 with, among others, AgeChem Venture Fund L.P. ("AgeChem") and Avrio (the "Equity Financing") and the redemption of the 58,083,334 pre-Consolidation common share purchase warrants held by AgeChem (the "Redemption of the AgeChem Warrants"), which have been closed in escrow on November 20, 2009. The approval of the TSX-V being the only condition to the release of the escrow, the escrow has now been lifted.
-
November
25
THE TSX VENTURE EXCHANGE APPROVES THE CONSOLIDATION OF THE SHARES OF ADVITECH AS PART OF THE MERGER OF ITS OPERATIONS WITH BOTANECO
TSX VENTURE EXCHANGE: AVI For immediate releaseThis news release is intended for distribution in Canada only and is not intended for distribution to United States newswire services or dissemination in the United States.
QUEBEC CITY, QUEBEC - November 25, 2009 - Advitech Inc. ("Advitech" or the "Corporation") (TSX Venture Exchange: AVI) announced today that the TSX Venture Exchange Inc. (the "TSX-V") approved the previously announced consolidation of its issued and outstanding common shares on the basis of a ratio of eight pre?Consolidation shares for every one post-Consolidation share (the "Consolidation") and that the common shares of Advitech will be traded on a post-Consolidation basis starting November 26, 2009.
-
November
20
ADVITECH CONSOLIDATES ITS COMMON SHARES AS PART OF THE MERGER OF ITS OPERATIONS WITH BOTANECO
TSX VENTURE EXCHANGE: AVI For immediate release
This news release is intended for distribution in Canada only and is not intended for distribution to United States newswire services or dissemination in the United States.
QUEBEC CITY, QUEBEC - November 20, 2009 - Advitech Inc. ("Advitech" or the "Corporation") (TSX Venture Exchange: AVI) announced today that it has completed, in escrow, subject to the approval of the TSX Venture Exchange Inc. (the "TSX-V"), the previously announced acquisition of all the issued and outstanding shares of Botaneco Specialty Ingredients Inc. ("Botaneco") held by Avrio Ventures Limited Partnership ("Avrio") and SemBioSys Genetics Inc. ("SemBioSys") (the "Transaction"), an equity financing in the amount of $2,515,000 with, among others, Agechem L.P Venture ("Agechem") and Avrio (the "Equity Financing") and the redemption of the 58,083,333 pre-Consolidation common share purchase warrants held by AgeChem (the "Redemption of the AgeChem Warrants"). The Transaction will be more fully described in a subsequent press release upon receipt of the approval of the TSX-V which is the only condition to be satisfied for the release of the escrow.
-
October
19
ADVITECH TO MERGE ITS ACTIVITIES WITH BOTANECO SPECIALTY INGREDIENTS INC.
TSX VENTURE EXCHANGE: AVI For immediate release
This news release is intended for distribution in Canada only and is not intended for distribution to United States newswire services or dissemination in the United States.
QUEBEC CITY, QUEBEC - October 19, 2009 - Advitech Inc. ("Advitech" or the "Corporation") (TSX Venture Exchange: AVI) announced today that it has entered into an arm's length definitive agreement dated October 19, 2009 to acquire all of the issued and outstanding shares of Botaneco Specialty Ingredients Inc. ("Botaneco") held by Avrio Ventures Limited Partnership ("Avrio") and SemBioSys Genetics Inc. ("SemBioSys"). This transaction will be effected by issuing to Avrio and SemBioSys a total of 224,792,020 common shares of Advitech (or 28,099,003 post-Consolidation common shares), at a deemed issuance price of $0.02 per share (or $0.16 per post-Consolidation common shares) which will represent 49% of all of the issued and outstanding shares of Advitech after closing of the transaction.
-
August
28
ADVITECH REPORTS SECOND QUARTER 2009 FINANCIAL RESULTS AND HIGHLIGHTS
TSX VENTURE EXCHANGE: AVI For immediate release
QUEBEC CITY, QUEBEC - August 28, 2009 - Advitech Inc. ("Advitech" or the "Corporation") (TSX Venture Exchange: AVI) today announces the financial results and highlights for the second quarter ended June 30, 2009.
-
June
11
ADVITECH’S DERMYLEX ENTERS THE AUSTRIAN MARKET
TSX VENTURE EXCHANGE: AVI For immediate release
QUEBEC CITY, QUEBEC - June 11, 2009 - Advitech Inc. ("Advitech" or the "Corporation") (TSX Venture Exchange: AVI) today announces the execution of an exclusive agreement with Pelpharma Handels GmbH ("Pelpharma") for the distribution of Dermylex® in Austria.
-
May
29
ADVITECH REPORTS FIRST QUARTER 2009 FINANCIAL RESULTS AND HIGHLIGHTS
TSX VENTURE EXCHANGE: AVI For immediate release
QUEBEC CITY, QUEBEC - May 29, 2009 - Advitech Inc. ("Advitech" or the "Corporation") (TSX Venture Exchange: AVI) today announces the financial results for the first quarter ended March 31, 2009.
-
May
26
ADVITECH TO PRESENT RECENT DATA ON WOUND HEALING AT THE GORDON RESEARCH CONFERENCE
TSX VENTURE EXCHANGE: AVI FOR IMMEDIATE RELEASE
Quebec CITY, QuEbec - May 26, 2009 - Advitech Inc. ("Advitech" or the "Corporation") (TSX Venture Exchange: AVI) today announced that Dr Charles Doillon, M.D., Ph.D., Researcher at Centre de Recherche du Centre Hospitalier de l'Université Laval, who is leading Advitech's wound healing program, will be presenting a progress report on the Corporation's IM technological platform for wound management at Gordon Research Conference ("GRC") on Tissue Repair and Regeneration at Colby-Sawyer College, New London, NH, on Thursday June 18th, 2009.
-
May
07
ADVITECH ANNONCES POSITIVE RESULTS IN WOUND HEALING
TSX VENTURE EXCHANGE: AVI FOR IMMEDIATE RELEASE
Quebec CITY, QuEbec - May 7, 2009 - Advitech Inc. ("Advitech" or the "Corporation") (TSX Venture Exchange: AVI) announces today new in vivo data from its R&D wound healing program confirming once again the potential of the IM technology platform for wound healing applications.
-
April
17
ADVITECH OBTAINS SHAREHOLDERS APPROVAL OF THE PRIVATE PLACEMENT WITH AGECHEM AND PROCEEDS WITH THE CONVERSION OF DEBENTURES
TSX VENTURE EXCHANGE: AVI For immediate release
This news release is intended for distribution in Canada only and is not intended for distribution to United States newswire services or dissemination in the United States.
2 3 4 5 6